Compass Therapeutics Stock Fundamentals
| CMPX Stock | USD 2.46 0.01 0.40% |
Compass Therapeutics fundamentals help investors to digest information that contributes to Compass Therapeutics' financial success or failures. It also enables traders to predict the movement of Compass Stock. The fundamental analysis module provides a way to measure Compass Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Compass Therapeutics stock.
At this time, Compass Therapeutics' Tax Provision is fairly stable compared to the past year. Net Interest Income is likely to rise to about 7.7 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 1.7 M in 2025. Compass | Select Account or Indicator |
Compass Therapeutics Company Current Valuation Analysis
Compass Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Compass Therapeutics Current Valuation | 221.47 M |
Most of Compass Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Compass Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Compass Current Valuation Historical Pattern
Today, most investors in Compass Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Compass Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Compass Therapeutics current valuation as a starting point in their analysis.
Compass Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Compass Therapeutics has a Current Valuation of 221.47 M. This is 98.46% lower than that of the Biotechnology sector and 95.23% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.67% higher than that of the company.
Compass Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Compass Therapeutics's current stock value. Our valuation model uses many indicators to compare Compass Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Compass Therapeutics competition to find correlations between indicators driving Compass Therapeutics's intrinsic value. More Info.Compass Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Compass Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Compass Therapeutics' earnings, one of the primary drivers of an investment's value.Compass Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Compass Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Compass Therapeutics could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics of similar companies.Compass Therapeutics is currently under evaluation in current valuation category among its peers.
Compass Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Compass Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Compass Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Compass Fundamentals
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (66.62) % | ||||
| Current Valuation | 221.47 M | ||||
| Shares Outstanding | 138.28 M | ||||
| Shares Owned By Insiders | 18.08 % | ||||
| Shares Owned By Institutions | 70.94 % | ||||
| Number Of Shares Shorted | 3.53 M | ||||
| Price To Book | 2.73 X | ||||
| Price To Sales | 400.20 X | ||||
| Revenue | 850 K | ||||
| Gross Profit | 850 K | ||||
| EBITDA | (56.04 M) | ||||
| Net Income | (49.38 M) | ||||
| Cash And Equivalents | 132.02 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 15.17 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.36 X | ||||
| Book Value Per Share | 0.91 X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Short Ratio | 3.05 X | ||||
| Earnings Per Share | (0.36) X | ||||
| Target Price | 11.4 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 340.17 M | ||||
| Total Asset | 140.4 M | ||||
| Retained Earnings | (364.68 M) | ||||
| Working Capital | 123.88 M | ||||
| Net Asset | 140.4 M |
About Compass Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Compass Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compass Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compass Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3.6 M | 2 M | |
| Total Revenue | 850 K | 892.5 K | |
| Cost Of Revenue | 1.7 M | 1.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.